Investigating the efficacy of tranexamic acid (TXA) as a prophylactic agent in reducing postpartum haemorrhage (PPH) among patients undergoing cesarean section (CS) in SQUH: a prospective randomized controlled trial.
Previous Caesarean Section
Multiple pregnancy,
Polyhydramnios,
Fetal macrosomia (BW >4kg),
Placenta accreta spectrum,
Contraindications to tranexamic acid (e.g., hypersensitivity to tranexamic acid), -History of seizure disorders,
Kidney disease,
Thromboembolic disease,
Parallel
tranexamic acid (1 g diluted in 100 mL of 0.9% saline
DrugThis intervention is currently used for treatment of postpartum hemorrhage and not a routine prophylaxis
Normal (0.9%) saline
DrugIntravenous volume matched normal 0.9% saline
Measured blood loss from skin incision to 24 hours postpartum using calibrated drapes (intra-op)
Measured blood loss from skin incision to 24 hours postpartum using calibrated drapes (intra-op) + gravimetric method (pads/linens) and suction canister accounting for irrigation, and Incidence of PPH ≥1000 mL within 24 hours after CS.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
